Efficacy of Thalidomide in the Treatment of Hereditary Hemorrhagic Telangiectasia (THALI-HHT)
Recruitment status was Recruiting
Hereditary hemorrhagic telangiectasia (HHT) (OMIM 187300 and 600376), also known as Rendu-Osler-Weber syndrome, is an autosomal dominant disease and has a prevalence between 1:5000 and 1:8000 in different populations. Clinically, the occurrence of mucocutaneous and gastrointestinal telangiectasias and of systemic arteriovenous malformations is commonly observed. Recurrent and severe epistaxis, due to the presence of telangiectasias in nasal mucosa, is the most common presentation of HHT, frequently leading to severe anemia requiring intravenous iron and blood transfusions. Although not life threatening, severe epistaxis has a great impact on quality of life in HHT patients and it represents the most important impediment in daily activities, that poses therapeutic challenge. Recently, angiogenesis has been implicated in the pathogenesis of HHT. Circulating concentrations of both TGF-beta and vascular endothelial growth factor (VEGF) are significantly elevated and therefore, anti-angiogenic substances may be effective in the treatment of vascular malformations in this disease. Thalidomide functions as a potent immunosuppressive and antiangiogenic agent. The aim of this study is to assess the clinical effects of thalidomide therapy on the severity of epistaxis in subjects with HHT who are refractory to standard therapies.
Hereditary Hemorrhagic Telangiectasia
|Study Design:||Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Efficacy of Thalidomide in the Treatment of Severe Recurrent Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)|
- Percentage of patients showing a decrease in the frequency, intensity and duration of epistaxis and in the blood transfusion requirement. [ Time Frame: up to 24 weeks ] [ Designated as safety issue: No ]Cessation of nose bleeding will be defined as complete response. Reduction in the severity of any bleeding parameter less than complete response will represent partial response.
- Size and number of telangiectasias evaluated by endoscopy of nasal mucosa (recording images of the size and localization of telangiectasias) [ Time Frame: up to 24 weeks ] [ Designated as safety issue: No ]
- Minimum dose of the drug that reduces bleeding [ Time Frame: up to 24 weeks ] [ Designated as safety issue: No ]
- Time to response [ Time Frame: up to 24 weeks ] [ Designated as safety issue: No ]
- Time to relapse after the end of treatment [ Time Frame: up to 24 weeks after the end of treatment ] [ Designated as safety issue: No ]
- Number of adverse events [ Time Frame: up to 1 year ] [ Designated as safety issue: Yes ]
- Correlations between biological parameters, response to treatment and side effects profile [ Time Frame: up to 24 weeks ] [ Designated as safety issue: Yes ]
- Correlations between the mutations that are responsible for HHT and response to treatment
- Correlations between polymorphisms of CYP2C19 and response to treatment
- Correlations between polymorphisms of CYP2C19 and side effects profile
|Study Start Date:||November 2011|
|Estimated Primary Completion Date:||January 2014 (Final data collection date for primary outcome measure)|
- 8 additional weeks of treatment after the achievement of complete response
- 16 additional weeks of treatment after the achievement of partial response
- 24 weeks of treatment completed without response
- unacceptable toxicity. Then, patients will be followed off of thalidomide for 24 weeks.
Eligible patients will receive thalidomide at a starting dose of 50 mg/day by mouth at bedtime for 4 weeks. In the event of unsatisfactory/no response, thalidomide dosage will be progressively increased by 50 mg/day every 4 weeks until complete or partial response, to a maximum dose of 200 mg/day.
Treatment will be continued until one of the following criteria is met:
In the management of HHT epistaxis, multiple approaches have been tried, including electrocautery, laser, embolization, arterial ligation, but all approaches are largely palliative with variable results, many requiring repeated interventions. Except for nasal closure, surgical options offer, at best, limited hemorrhage-free intervals, but no definitive results and all have side effects. Moreover, currently, there is no established medical treatment available for these patients. To limit blood loss, the few medical treatments used include manipulation of the coagulation and fibrinolytic pathways or topical applications of anti-inflammatory drugs. However, multiple lesions disseminated over the entire mucosal surface are common in affected individuals, making local treatment difficult. Re-bleeding consumes a disproportionate share of healthcare resources devoted to multiple admissions, repeated endoscopies and blood transfusions.
Recently, angiogenesis has been implicated in the pathogenesis of HHT. Circulating concentrations of both TGF-beta and vascular endothelial growth factor (VEGF) are significantly elevated and therefore, anti-angiogenic substances may be effective in the treatment of vascular malformations in this disease.
Thalidomide functions as a potent immunosuppressive and antiangiogenic agent by inhibiting the phagocytic ability of inflammatory cells and the production of cytokines, such as tumor necrosis factor-alpha (TNF-a). It has been shown to be effective in the treatment of inflammatory diseases, in conditions associated with human immunodeficiency virus (HIV) infection, and in various cancers. Bleeding inhibition has been observed in HHT patients who received thalidomide as an antiangiogenic cancer therapy. A recent paper has reported that thalidomide treatment induced vessel maturation in an experimental model of HHT and reduced severe nosebleeds in six of the seven HHT patients studied. On the other hand, spectacular improvements have been described in patients with intestinal angiodysplasias, treated with thalidomide. In isolated case reports, patients with severe recurrent intestinal bleeding refractory to standard treatment achieved prolonged complete remission with thalidomide at a dose of 100 to 300 mg/day for a few months and tolerance was good. Cessation of bleeding was associated with a reduction in serum VEGF levels. These observations suggest that thalidomide might be useful for treatment of HHT patients and address significant unmet medical needs. Unfortunately, this drug exposes patients to the risk of severe side effects.
Drug metabolism is under control of a number of enzymes specific for each drug; among these enzymes, many show variable levels of activity and we can thus recognize in the population extensive (high or fast) metabolizers (EM) intermediate (IM) and poor (low or slow) metabolizers (PM). This is true also for thalidomide, whose metabolism is in part controlled by the enzyme CYP2C19.
The aims of our study are to test the hypothesis that thalidomide reduces the bleeding tendency of HHT patients and to verify to which extent CYP2C19 polymorphism modulates both response to treatment and side effects.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01485224
|Contact: Rosangela Invernizzi, M.D.||0039 0382 email@example.com|
|Contact: Francesca Bellistri, M.D.||0039 0382 firstname.lastname@example.org|
|Clinica Medica 3, Fondazione IRCCS Policlinico S. Matteo||Recruiting|
|Pavia, Italy, 27100|
|Contact: Rosangela Invernizzi, M.D. 0039 0382 502160 email@example.com|
|Contact: Francesca Bellistri, M.D. 0039 0382 502169 firstname.lastname@example.org|
|Sub-Investigator: Gabriella Gamba, M.D.|
|Sub-Investigator: Marco Benazzo, M.D.|
|Sub-Investigator: Cesare Danesino, M.D.|
|Sub-Investigator: Fabio Pagella, M.D.|
|Sub-Investigator: Cecilia Canzonieri, M.D.|
|Sub-Investigator: Francesco Chu, M.D.|
|Sub-Investigator: Elina Matti, M.D.|
|Sub-Investigator: Carla Olivieri, M.D.|
|Sub-Investigator: Federica Ornati, M.D.|
|Principal Investigator:||Carlo Balduini, M.D.||Fondazione IRCCS Policlinico S. Matteo, Pavia, Italy|